A clinical trial evaluates a new monoclonal antibody. The volume of distribution () is calculated to be in a adult subject. This value suggests that the drug is distributed primarily in which physiologic fluid compartment?
Answer and explanation
Correct answer: A. Plasma compartment only
- Step 1: Review physiological fluid volumes for a standard adult: plasma volume is approximately ( body weight), extracellular fluid (ECF) volume is (), and total body water (TBW) is ().
- Step 2: Large macromolecular therapeutics like monoclonal antibodies (MW ) and highly plasma protein-bound drugs cannot readily cross capillary fenestrations. A of approximates total plasma volume, indicating near-complete intravascular confinement.
Answer
Plasma compartment only.
Why not the others: Extracellular fluid compartment (plasma + interstitial fluid) corresponds to a of approximately , typical of small, hydrophilic molecules (e.g., aminoglycosides); Total body water corresponds to a , typical of small lipophilic uncharged molecules (e.g., ethanol, phenytoin); Sequestration in adipose and deep tissues yields very high apparent values exceeding total body weight (e.g., chloroquine, digoxin, amiodarone, where ).
Practise more General Pharmacology and Autonomic Pharmacodynamics.
Free questions with an explanation for every one, and full timed USMLE Step 1 mock tests.
More General Pharmacology and Autonomic Pharmacodynamics questions
- A competitive antagonist shifts the agonist dose-response curve in which direction without altering the maximal efficacy ()?
- A 65-year-old man with benign prostatic hyperplasia and chronic open-angle glaucoma receives an over-the-counter cold medication containing…
- A drug follows first-order elimination kinetics. If its elimination half-life () is , what percentage of the in…
- A 32-year-old farmer is rushed to the emergency department with excessive salivation, lacrimation, urination, defecation, bronchospasm, and…
- A 58-year-old woman undergoing chemotherapy with cyclophosphamide is prescribed Mesna to prevent which dose-limiting adverse effect?